Figure 3
![Figure 3. WST-1 viability assay on PIPLC-treated EA.hy926 cells. Percentage of nonviable PIPLC-treated EA.hy926 cells among different disease entities (data are presented as mean with standard error of the mean [SEM]). aPIGN, atypical postinfectious glomerulonephritis; Ecu-aHUS, atypical hemolytic uremic syndrome treated with eculizumab; Stec-HUS: Shiga-toxin–associated hemolytic uremic syndrome.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/125/23/10.1182_blood-2015-02-629683/4/3637f3.jpeg?Expires=1722763537&Signature=zzVXvdFLC49A2rD1~TfW7Sh7AX3iUa6ANUa2W3c99EBwlJKPei4t1gpDOQ~ZoVRkYlZXPPY~SvdmtGkY44CpS31Ury6ctxnJsBrQdMLj-cG~593mRyRDsadonwuVGlAR2nOsDcWm1NEPnP8FZGiQKYBIsXTEi18fIIDxI-v8rG0oiLac0wsE0ZXtEG-c1W7-I8uDNedRFO5mjWvQRIs5dR2LtMsrROcMzB0eQKiD6YnczmdIqeZverueT64~BmMqwxArOuoCztBZZv-awnX7HhlhjudJ-lZE1Q60iuO1ofl1s-b0Tlrga-8mlfBdwgkAIYMSpbq9a4f8WKfKAwBOJw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
WST-1 viability assay on PIPLC-treated EA.hy926 cells. Percentage of nonviable PIPLC-treated EA.hy926 cells among different disease entities (data are presented as mean with standard error of the mean [SEM]). aPIGN, atypical postinfectious glomerulonephritis; Ecu-aHUS, atypical hemolytic uremic syndrome treated with eculizumab; Stec-HUS: Shiga-toxin–associated hemolytic uremic syndrome.
